ZA985410B - Use of somatostatin agonists and antagonists for treating diseases related to the eye - Google Patents
Use of somatostatin agonists and antagonists for treating diseases related to the eyeInfo
- Publication number
- ZA985410B ZA985410B ZA985410A ZA985410A ZA985410B ZA 985410 B ZA985410 B ZA 985410B ZA 985410 A ZA985410 A ZA 985410A ZA 985410 A ZA985410 A ZA 985410A ZA 985410 B ZA985410 B ZA 985410B
- Authority
- ZA
- South Africa
- Prior art keywords
- antagonists
- eye
- treating diseases
- diseases related
- somatostatin receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK74797 | 1997-06-24 | ||
| US5130097P | 1997-06-30 | 1997-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA985410B true ZA985410B (en) | 1999-01-04 |
Family
ID=26064570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA985410A ZA985410B (en) | 1997-06-24 | 1998-06-22 | Use of somatostatin agonists and antagonists for treating diseases related to the eye |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1019050B1 (ja) |
| JP (1) | JP2002515912A (ja) |
| AT (1) | ATE214604T1 (ja) |
| AU (1) | AU7907198A (ja) |
| DE (1) | DE69804332T2 (ja) |
| DK (1) | DK1019050T3 (ja) |
| ES (1) | ES2174447T3 (ja) |
| PT (1) | PT1019050E (ja) |
| WO (1) | WO1998058646A1 (ja) |
| ZA (1) | ZA985410B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2246791A1 (en) * | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
| FR2796945B1 (fr) | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
| AR030946A1 (es) | 2000-09-20 | 2003-09-03 | Schering Corp | Derivados de imidazoles sustituidos un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos como agonistas o antagonistas duales de h1 y h3 de histamina |
| CA2422210C (en) | 2000-09-20 | 2009-10-27 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| MXPA03002447A (es) | 2000-09-20 | 2003-07-21 | Schering Corp | Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina. |
| DE60107586T2 (de) | 2000-09-20 | 2005-10-06 | Schering Corp. | Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten |
| WO2004039403A1 (ja) * | 2002-10-31 | 2004-05-13 | Senju Pharmaceutical Co., Ltd. | 角膜障害治療剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0912551A1 (en) * | 1996-05-14 | 1999-05-06 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| AU4772497A (en) * | 1996-10-31 | 1998-05-22 | Novo Nordisk A/S | Constrained somatostatin agonists and antagonists |
-
1998
- 1998-06-22 AT AT98929232T patent/ATE214604T1/de not_active IP Right Cessation
- 1998-06-22 ES ES98929232T patent/ES2174447T3/es not_active Expired - Lifetime
- 1998-06-22 DK DK98929232T patent/DK1019050T3/da active
- 1998-06-22 EP EP98929232A patent/EP1019050B1/en not_active Expired - Lifetime
- 1998-06-22 PT PT98929232T patent/PT1019050E/pt unknown
- 1998-06-22 ZA ZA985410A patent/ZA985410B/xx unknown
- 1998-06-22 AU AU79071/98A patent/AU7907198A/en not_active Abandoned
- 1998-06-22 DE DE69804332T patent/DE69804332T2/de not_active Expired - Fee Related
- 1998-06-22 WO PCT/DK1998/000267 patent/WO1998058646A1/en active IP Right Grant
- 1998-06-22 JP JP50361499A patent/JP2002515912A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002515912A (ja) | 2002-05-28 |
| DK1019050T3 (da) | 2002-07-08 |
| ATE214604T1 (de) | 2002-04-15 |
| AU7907198A (en) | 1999-01-04 |
| PT1019050E (pt) | 2002-09-30 |
| EP1019050A1 (en) | 2000-07-19 |
| DE69804332D1 (de) | 2002-04-25 |
| EP1019050B1 (en) | 2002-03-20 |
| ES2174447T3 (es) | 2002-11-01 |
| DE69804332T2 (de) | 2002-11-07 |
| WO1998058646A1 (en) | 1998-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MooreLori et al. | Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma | |
| RU2470635C2 (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
| EP0743852B1 (en) | Treatment of normotensive glaucoma with valsartan | |
| CA2331053A1 (en) | Compositions and methods for treating conditions responsive to estrogen | |
| WO2003047513A3 (en) | Method for treating ocular hypertension | |
| DE60307607D1 (de) | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten | |
| HK1015691A1 (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia. | |
| HK1069851A1 (en) | Bone morphogenic proteins (bmp), bmp receptors andbmp binding proteins and their use in the diagnosis and treatment of glaucoma | |
| SG189177A1 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2008505173A (ja) | 痛みおよび他のα２アドレナリン作動性仲介状態を処置するための方法および組成物 | |
| WO2010113753A1 (ja) | ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用 | |
| US20110130388A1 (en) | Prophylactic or therapeutic agent for axial myopia | |
| ZA985410B (en) | Use of somatostatin agonists and antagonists for treating diseases related to the eye | |
| ATE487514T1 (de) | 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom | |
| US10485786B2 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
| JP2004182723A (ja) | Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
| DK1395263T3 (da) | 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk | |
| CN113227086A (zh) | 作为用于治疗神经视网膜疾病的视网膜前体细胞的生产的刺激剂的n-(4-(噁唑-5-基)苯基)色满-3-甲酰胺衍生物及相关化合物 | |
| JP2008285478A (ja) | アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤 | |
| WO2004047868A1 (ja) | Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤 | |
| AU656547B2 (en) | Use of pyridine derivatives in the treatment of ocular hypertension | |
| Greener | Sights set on neuroprotection for glaucoma | |
| WO2002030420A1 (fr) | Remedes pour maladies du nerf optique, contenant des derives de 1,2-ethanediol ou des sels correspondants | |
| JP2003081874A (ja) | α１受容体遮断薬を有効成分とする視神経保護剤 | |
| Bonomi et al. | Effects of intraocular dapiprazole in the rabbit eye |